
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is a leader in the fast-growing market of genetic testing, with a diverse portfolio of products that address significant medical needs. Management's focus on MRD monitoring is supported by strong clinical data and a dominant market position, providing a solid foundation for continued growth and profitability. The company's strong track record of securing reimbursement and expanding their clinical indications bodes well for their future success and potential for further upside.
Bears say
Natera is facing intense competition in the MRD and NIPT markets, with multiple well-funded players vying for market share in these key areas. While Natera may have a strong moat with its ultra-sensitive testing technology, there is a risk that competitors could replicate or innovate similar products, eroding Natera's competitive advantage. Additionally, there are uncertainties surrounding the timely realization of key catalysts, as well as potential headwinds to margin expansion from higher COGS and ASP growth.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares